The Department of Health and Human Services today delayed until July 1, 2019 implementation of its final rule on 340B drug ceiling prices and civil monetary penalties for manufacturers. "With skyrocketing prescription drug price increases presenting hospitals, health systems and patients with remarkable challenges, the 340B program is as critical as ever in helping provide access to health care services for vulnerable patients and communities,” said AHA Executive Vice President Tom Nickels. “The 340B ceiling price and civil monetary penalties rule were intended to shine needed light on drug manufacturer price increases and hold drug manufacturers accountable for price overcharging. These reasons are why we continue to be disappointed in the delays – including five times since the beginning of last year alone – of the final rule and in the short shrift given to the review of the latest public comments. The irony is not lost on us that drug manufacturers continue to lobby for increased reporting for hospitals and others while refusing any transparency on their part."

Related News Articles

Insights and Analysis
In this guest column, Kenneth Kaufman, chair of Kaufman Hall, discusses how hospitals need scale to keep pace in today’s environment, as well as continue to…
Chairperson's File
We look ahead with optimism as we advance the goals of improving health care quality, equity, access and affordability for all Americans.  
The Federal Trade Commission’s approach to reviewing hospital mergers “is overbroad, does not properly credit the many pro-consumer benefits of hospital…
The AHA today voiced support for a Centers for Medicare…
The AHA’s Institute for Diversity and Health Equity today named Duane Elliott Reynolds as its new president and CEO.
A federal judge in Texas last night ruled that the entire Affordable Care is unconstitutional because Congress repealed the tax penalty enforcing the law's…